- Home
- ITRG vs BCAB Comparison
ITRG vs BCAB Comparison
Compare ITRG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRG | BCAB |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.5M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ITRG | BCAB |
|---|---|---|
| Price | $4.35 | $0.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $4.13 | $1.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.1M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $219,125,000.00 | N/A |
| Revenue This Year | $1,016.77 | N/A |
| Revenue Next Year | $7.81 | N/A |
| P/E Ratio | $56.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.79 | $0.24 |
| 52 Week High | $4.69 | $1.43 |
Technical Indicators
Market Signals| Indicator | ITRG | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 44.92 |
| Support Level | $4.01 | $0.63 |
| Resistance Level | $4.69 | $0.83 |
| Average True Range (ATR) | 0.25 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 70.75 | 37.10 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.